Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells

The double-strand break-free approach increased functional GATA2 alleles and improved the engraftment of edited blood stem cells in mice

October 21, 2026
3 min

The Medicine Maker

At a Glance

Category	Detail
Condition	GATA2 deficiency, a rare inherited disorder caused by mutations affecting one copy of the GATA2 gene.
Key Mechanisms	Prime editing uses a modified Cas9 protein and reverse transcriptase to rewrite a targeted DNA sequence without cutting both DNA strands.
Target Population	Patient-derived CD34-positive hematopoietic stem and progenitor cells carrying a seven-base-pair GATA2 deletion.
Care Setting	Preclinical gene-editing research using patient-derived cells and transplantation into immunodeficient mice.

Key Highlights

Prime editing reached efficiencies above 70% in CD34-positive cells after optimization.
The proportion of functional GATA2 alleles increased from an expected baseline of 50% to as much as 77%, with increased GATA2 protein expression.
Edited cells retained blood-cell colony-forming capacity and showed up to 2.73-fold greater engraftment than untreated cells in immunodeficient mice.
Editing persisted in repopulating stem cells 16 weeks after transplantation.
PASSIGE-mediated insertion of a larger corrective sequence reached 4.6% of alleles.

Guideline-Based Recommendations

Diagnosis

Management

The study evaluated prime editing as a preclinical approach to repair a disease-causing GATA2 mutation in patient-derived stem and progenitor cells.
Allogeneic hematopoietic stem cell transplantation is described as the only current curative treatment for GATA2 deficiency.

Monitoring & Follow-up

Researchers assessed editing efficiency, GATA2 protein expression, cell fitness, colony formation, engraftment, persistence of editing, and unintended edits.

Risks

GATA2 deficiency can involve severe infections, bone marrow failure, and increased risk of myeloid cancers.
Allogeneic hematopoietic stem cell transplantation carries risks including graft-versus-host disease and graft failure.
The study reported limited unintended changes at the target site and no editing at the 20 highest-ranked predicted off-target sites.

Patient & Prescribing Data

The research used patient-derived CD34-positive hematopoietic stem and progenitor cells; it did not report treatment of patients.

Prime editing was studied preclinically and is not presented as an established patient treatment. PASSIGE insertion efficiency was 4.6% of alleles and requires further optimization.

Clinical Best Practices

The study found that shortening stem-cell stimulation to less than 24 hours reduced the DNA damage response and improved multilineage engraftment.
The researchers assessed predicted off-target sites and cell function as part of evaluating the editing approach.